Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Using Idun Purchase As Model For Future M&A

This article was originally published in The Pink Sheet Daily

Executive Summary

Pfizer is using its acquisition of Idun Pharmaceuticals as a new model for how it looks at M&A: allowing acquired companies to operate independently of Pfizer's big pharma machine

You may also be interested in...



Pfizer Clarifies M&A Philosophy

Pfizer's acquisition of Idun should not be viewed as a "departure" from the company's historical approach to mergers and acquisitions, Pfizer Senior VP-Science & Technology Peter Corr said in a letter to "The Pink Sheet" DAILY

Pfizer Clarifies M&A Philosophy

Pfizer's acquisition of Idun should not be viewed as a "departure" from the company's historical approach to mergers and acquisitions, Pfizer Senior VP-Science & Technology Peter Corr said in a letter to "The Pink Sheet" DAILY

Pfizer’s Acquisition Of Idun Includes Phase II Caspase Inhibitor

Idun’s lead small molecule, IDN-6556, is thought to control apoptosis (cell death) and is in Phase II trials for liver transplantation and hepatitis C. The deal is expected to close in the second quarter.

Topics

UsernamePublicRestriction

Register

MT125529

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel